Temozolomide in malignant glioma

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 139-146

  Dresemann, Gregor ^a  

^a Department of Neurology   (Germany)

Author keywords

Astrocytoma WHO grade III; Glioblastoma multiforme; Malignant glioma; Temozolomide

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CEDIRANIB; CELECOXIB; CETUXIMAB; CILENGITIDE; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GEFITINIB; HYDROXYUREA; IRINOTECAN; LAPATINIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PACLITAXEL; PANITUMUMAB; PROCARBAZINE; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM METASTASIS; COMORBIDITY; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; FUNCTIONAL STATUS; GLIOBLASTOMA; HERPES VIRUS INFECTION; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROSURGERY; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; REVIEW; SURGICAL APPROACH; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

EID: 84862177003     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/ott.s5480     Document Type: Review

References (76)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon, France: IARC; 2007.
2. Eoli M, Menghi F, Bruzzone MG, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozigosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007;13:2606-2613.
3. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neurooncol. 2007;9:314-318.
4. Cairncross G, Seiferheld W, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24: 2707-2714.
5. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in normal and pathologic brain. Nat Neurosci. 2007;10: 1387-1397.
6. Carapancea M, Alexandru O, Fetea A, et al. Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol. 2009;92:137-147.
7. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995;60: 168-173.
8. Hermanson M, Funa K, Hartman M, et al. Plateletderived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52:3213-3219.
9. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumor. Nat Rev Neurosci. 2007;8:610-622.
10. Pelloski C, Ballman K, Furth A, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25:2288-2294.
11. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
12. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84:6899-6903.
13. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the avh3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991;88:1924-1932.
14. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006;66:11502-11513.
15. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
16. Friedman H, McLendon R, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857.
17. Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900-2908.
18. Beith J, Cook R, Robinson BLJ, et al. Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high grade gliomas. Proc Am Assoc Cancer Res. 1997;16:386.
19. Friedman HS. Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic? Clin Cancer Res. 2000;6:2967-2968.
20. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753-766.
21. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol. 2006;7:392-401.
22. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008-1012.
23. Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncol Rep. 2000;7:899-904.
24. Hau P, Baumgart U, Pfeifer K, Bock A, et al. Salvage therapy in patients with glioblastoma: is there any benefit. Cancer. 2003;98:2678-2686.
25. Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2009;92:185-191.
26. Westphal M, Hilt DC, Bortey E, et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol. 2003;5:79-88.
27. Wolff JE, Berrak S, Koontz Webb SE, et al. Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol. 2008;88:57-63.
28. Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer. 2003;97:2363-2373.
29. Brandes AA, Ermani M, Turazzi S, et al. Procarbazine and high-dose tamoxifen as a second- line regimen in recurrent high-grade gliomas: a phase ii study. J Clin Oncol. 1999;17:645-650.
30. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-2722.
31. Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-1329.
32. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med. 2001;345:621-622.
33. Brada M, Judson I, Beale P, et al. Phase I dose-excalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81:1022-1030.
34. ÓReilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer. 1993;29:940-942.
35. Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide. A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35-61.
36. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20:2388-2399.
37. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933-4938.
38. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
39. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse, Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-2771.
40. Kim SH, Park TS, Lee ST, et al. Therapy-related myelodysplasia/acute myeloid leucemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci. 2009;39:392-398.
41. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-266.
42. Franceschi E, Omuro AM, Lassman AB, et al. Salvage temozolomide for prior temozolomide responders. Cancer. 2005;104:2473-2476.
43. Happold C, Roth P, Wick W, et al. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol. 2009;92:45-48.
44. Jauch T, Hau P, Bogdahn U. Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas. Proc ASCO. 2007;25:83s.
45. Kappelle AC, Postma TJ, Taphoorn MJB, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:118-120.
46. Kong DS, Lee JI, Kim WS, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006;16:1117-1121.
47. Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology. 2004;63:904-906.
48. Hegi ME, Liu L, Herman J, et al. Correlation of O6-Methylguanine Methyltransferase MGMT promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-4199.
49. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6- alkylguanine-DNA-alkyltansferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
50. Wick W, Steinbach JP, Kuker WM, et al. One week on/one week off: a novel active regimen for temozolomide for recurrent glioblastoma. Neurol. 2004;62:2113-2115.
51. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357-3361.
52. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperative di neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155-1160.
53. van Rijn J, Heimans JJ, van den Berg J, et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int J Radiat Oncol Biol Phys. 2000;47:779-784.
54. Wedge SR, Porteous JK, Glaser MG, et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997;8:92-97.
55. Stupp R, Hegi ME, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-180.
56. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
57. Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
58. Hegi M, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
59. Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed Glioblastoma. J Clin Oncol. 2009;27:3861-3867.
60. Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009; 115:3512-3518.
61. Chamberlain MC, Chalmers LM. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol. 2007;82:207-209.
62. Iwamoto FM, Coeper AR, Reiner AS, et al. Glioblastoma in the elderly: The Memorial Sloan-Kettering Cancer Center experience (1997-2007). Cancer. 2009;115:3758-3766.
63. Minniti G, De Sanelis V, Muni R, et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol. 2009;91:95-100.
64. Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high grade glioma. Neurology. 2007;68:688-690.
65. Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009;27:1257-1261.
66. Korones DN, Benita-Weiss M, Coyle TE, et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 2003;97:1963-1968.
67. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110:583-588.
68. Prados MD, Yung WKA, Fine HA, et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neurooncol. 2004;6:33-37.
69. Raizer JJ, Malkin MG, Kleber M, et al. Phase 1 study of 28-day, lowdose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neurooncol. 2004;6:247-252.
70. Silvani A, Eoli M, Salmaggi A, et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol. 2004;66:203-208.
71. Nicholas MK, Lukas RV, Jafri NF, et al. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006;12:7261-7270.
72. Prados M, Chang S, Butowski C, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579-584.
73. Prados MD, Lamborn KR, Chang S, et al. Phase I study of erlotinib HCI alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncol. 2006;8:67-78.
74. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71:1372-1380.
75. Gupta V, Su YS, Wang W, et al. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus. 2006;20(4):E20.
76. Spence AM, Peterson RA, Scharnhorst JD, et al. Phase II study of concurrent continous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol. 2004;70:91-95.